Imipenem resistance of Pseudomonas in pneumonia: a systematic literature review.
BACKGROUND
Pneumonia, and particularly nosocomial (NP) and ventilator-associated pneumonias (VAP), results in high morbidity and costs. NPs in particular are likely to be caused by Pseudomonas aeruginosa (PA), ~20% of which in observational studies are resistant to imipenem. We sought to identify the burden of PA imipenem resistance in pneumonia.


METHODS
We conducted a systematic literature review of randomized controlled trials (RCT) of imipenem treatment for pneumonia published in English between 1993 and 2008. We extracted study, population and treatment characteristics, and proportions caused by PA. Endpoints of interest were: PA resistance to initial antimicrobial treatment, clinical success, microbiologic eradication and on-treatment emergence of resistance of PA.


RESULTS
Of the 46 studies identified, 20 (N = 4,310) included patients with pneumonia (imipenem 1,667, PA 251; comparator 1,661, PA 270). Seven were double blind, and 7 included US data. Comparator arms included a β-lactam (17, [penicillin 6, carbapenem 4, cephalosporin 7, monobactam 1]), aminoglycoside 2, vancomycin 1, and a fluoroquinolone 5; 5 employed double coverage. Thirteen focused exclusively on pneumonia and 7 included pneumonia and other diagnoses. Initial resistance was present in 14.6% (range 4.2-24.0%) of PA isolates in imipenem and 2.5% (range 0.0-7.4%) in comparator groups. Pooled clinical success rates for PA were 45.2% (range 0.0-72.0%) for imipenem and 74.9% (range 0.0-100.0%) for comparator regimens. Microbiologic eradication was achieved in 47.6% (range 0.0%-100.0%) of isolates in the imipenem and 52.8% (range 0.0%-100.0%) in the comparator groups. Resistance emerged in 38.7% (range 5.6-77.8%) PA isolates in imipenem and 21.9% (range 4.8-56.5%) in comparator groups.


CONCLUSIONS
In the 15 years of RCTs of imipenem for pneumonia, PA imipenem resistance rates are high, and PA clinical success and microbiologic eradication rates are directionally lower for imipenem than for comparators. Conversely, initial and treatment-emergent resistance is more likely with the imipenem than the comparator regimens.
Zilberberg
Marya D
MD
School of Public Health and Health Sciences, University of Massachusetts, Amherst, MA, USA. Marya@evimedgroup.org
Chen
Joyce
J
Mody
Samir H
SH
Ramsey
Andrew M
AM
Shorr
Andrew F
AF
D000900:Anti-Bacterial Agents / Q000494:pharmacology / Q000627:therapeutic use*; D024881:Drug Resistance, Bacterial; D006801:Humans; D015378:Imipenem / Q000494:pharmacology / Q000627:therapeutic use*; D018410:Pneumonia, Bacterial / Q000188:drug therapy* / Q000382:microbiology; D053717:Pneumonia, Ventilator-Associated / Q000188:drug therapy* / Q000382:microbiology; D011552:Pseudomonas Infections / Q000188:drug therapy*; D011550:Pseudomonas aeruginosa / Q000187:drug effects*; D016032:Randomized Controlled Trials as Topic; D016896:Treatment Outcome
D000900:Anti-Bacterial Agents; D015378:Imipenem
Diagn Microbiol Infect Dis. 2002 Nov;44(3):301-11
12493178
Clin Infect Dis. 2001 May 15;32 Suppl 2:S146-55
11320454
Chest. 2002 Jul;122(1):262-8
12114368
Emerg Infect Dis. 2007 Dec;13(12):1840-6
18258033
Clin Ther. 2003 Feb;25(2):485-506
12749509
Clin Infect Dis. 1999 May;28(5):1008-11
10452626
Int J Antimicrob Agents. 2000 Jul;15(2):119-23
10854807
J Antimicrob Chemother. 2006 Sep;58(3):697-700
16895941
Antimicrob Agents Chemother. 2007 Oct;51(10):3568-73
17682100
Antimicrob Agents Chemother. 2004 Dec;48(12):4606-10
15561832
Curr Med Res Opin. 2006 May;22(5):843-50
16709306
Clin Infect Dis. 2004 May 1;38(9):1279-86
15127341
Thorax. 2000 Dec;55(12):1033-9
11083889
Respir Med. 2006 Sep;100(9):1554-65
16487695
Antimicrob Agents Chemother. 2006 Jan;50(1):43-8
16377665
Crit Care Med. 2008 Apr;36(4):1089-96
18379232
Cancer. 1996 Apr 1;77(7):1386-94
8608520
Clin Infect Dis. 2005 Feb 15;40 Suppl 2:S115-22
15712099
Antimicrob Agents Chemother. 2003 Nov;47(11):3442-7
14576100
Ann Hematol. 1994 Nov;69(5):231-43
7948312
Crit Care Med. 2002 Feb;30(2):349-54
11889308
Clin Infect Dis. 2005 Feb 15;40 Suppl 2:S123-9
15712100
J Hosp Infect. 2007 Mar;65(3):251-7
17257710
Infect Control Hosp Epidemiol. 2009 Feb;30(2):184-6
19125679
Intern Med. 2006;45(17):995-9
17015999
J Antimicrob Chemother. 1999 Mar;43 Suppl A:129-34
10225583
Intensive Care Med. 1996 May;22(5):387-94
8796388
Antimicrob Agents Chemother. 1994 Mar;38(3):547-57
8203853
J Chemother. 1995 Jun;7 Suppl 2:165-73
8622107
Am J Respir Crit Care Med. 2005 Feb 15;171(4):388-416
15699079
Pharmacotherapy. 1996 Sep-Oct;16(5):924-31
8888088
Infect Control Hosp Epidemiol. 2006 Sep;27(9):893-900
16941312
Crit Care. 2006;10(3):R78
16704742
Drugs. 1995;49 Suppl 2:436-8
8549392
J Chemother. 2002 Dec;14(6):609-17
12583553
Drugs. 1995;49 Suppl 2:439-41
8549393
J Antimicrob Chemother. 1993 Jun;31(6):927-37
8360130
Emerg Infect Dis. 2008 Nov;14(11):1756-8
18976563
Respiration. 1997;64(3):224-8
9154675
Diagn Microbiol Infect Dis. 1998 Dec;32(4):289-301
9934546
Infection. 1995 Nov-Dec;23(6):349-55
8655205
Hepatogastroenterology. 1999 Mar-Apr;46(26):1126-30
10370679
Eur Respir J. 2007 Mar;29(3):548-60
17329491
Infection. 2006 Jun;34(3):127-34
16804655
Eur J Pediatr. 1996 Nov;155(11):948-53
8911895
Rev Esp Quimioter. 2002 Sep;15(3):257-63
12582429
Clin Infect Dis. 1999 Oct;29(4):926-8
10589912
Antimicrob Agents Chemother. 1994 Jun;38(6):1309-13
8092830
Antimicrob Agents Chemother. 1998 Nov;42(11):2966-72
9797234
J Antimicrob Chemother. 1998 Dec;42(6):793-802
10052904
Antimicrob Agents Chemother. 2005 Apr;49(4):1306-11
15793102
Antimicrob Agents Chemother. 2007 Sep;51(9):3304-10
17620371
Drugs Exp Clin Res. 1999;25(6):243-52
10713862
Chest. 2003 Jun;123(6):1970-6
12796176
Zhonghua Yi Xue Za Zhi (Taipei). 2000 May;63(5):361-7
10862445
Int J Antimicrob Agents. 2001 Mar;17(3):177-88
11282262
J Chemother. 2006 Oct;18(5):502-6
17127227
JAMA. 1999 Jan 6;281(1):67-71
9892453
Drugs Exp Clin Res. 1993;19(5):223-7
8174495
Arch Surg. 1997 Oct;132(10):1086-92
9336506
Infect Control Hosp Epidemiol. 2007 Nov;28(11):1247-54
17926275
Am J Infect Control. 2004 Dec;32(8):470-85
15573054
Diagn Microbiol Infect Dis. 1998 Jun;31(2):355-68
9635910
Nat Biotechnol. 2006 Dec;24(12):1521-8
17160056